Achillion Pharmaceuticals
  • About Us
    • Overview
    • Business Development
  • Our Focus
    • Our Pipeline
    • Our Science
    • Complement Mediated Diseases
    • Scientific Presentations
  • Patients & Clinicians
    • Patients & Clinicians
    • Expanded Access Policy
  • Investors & News
  • Careers
    • Opportunities
    • Life at Achillion
  • Connect
  • Home
    •
  • About Achillion +
    •
    • Overview
      •
    • Our Team
      •
    • Board of Directors
      •
    • Business Development

  • Our Focus +
    •
    • Our Pipeline
    • Our Science
    • Complement Mediated Diseases
      •
    • Scientific Presentations 

  • Patients and Clinicians +
    •
    • Patients and Clinicians
    • Compassionate Use Policy

  • Investors & News +
    •
    • Overview
      •
    • Stock Information
      •
    • Press Releases
      •
    • Events & Presentations
      •
    • Annual Reports
      •
    • Financial Information
      •
    • Corporate Governance
      •
    • FAQs
      •
    • Contact Us

  • Careers +
    •
    • Opportunities
      •
    • Life at Achillion
      •
  • Connect
    •
  • Legal
    •
  • Privacy
    •
  • Cookies
    •

  • ABOUT ACHILLION
  • BUSINESS DEVELOPMENT

2

2

Achillion has been acquired by Alexion Pharmaceuticals, Inc.

For more information, click here.
Legal / Privacy / Cookies
This page was last updated on January 23, 2017 at 6:09 pm EST.
© 2020 Achillion Pharmaceuticals, Inc. All rights reserved.
Home
About Achillion
Our Focus
Patients and Clinicians
Investors & News
Careers
Connect
Achillion Pharmaceuticals, Inc.
1777 Sentry Parkway West
VEVA Building #14,
Suite 200
Blue Bell, Pennsylvania 19422
main +215-709-3040